API | duvelisib

duvelisib (copiktra) Report issue

Small molecule Orphan Drug ^FDA Approved ^FDA Fast Track ^FDA Accelerated Approval ^FDA Priority Review ^FDA

AACT ChEMBL DrugBank Drugs@FDA MeSH PubChem

Active Ingredient History

NOW

Duvelisib (IPI-145), is an orally available, small-molecule, selective dual inhibitor of phosphatidylinositol 3 kinase (PI3K) δ and γ isoforms originated by Intellikine (owned by Takeda) and developed by Infinity Pharmaceuticals. Orally administered duvelisib was rapidly absorbed, with a dose-proportional increase in exposure. The compound produced a half-life of approximately 7-12 hours, following 14 days of dosing. Duvelisib exerts profound effects on adaptive and innate immunity by inhibiting B and T cell proliferation, blocking neutrophil migration, and inhibiting basophil activation. Duvelisib blockade of PI3K-δ and PI3K-γ potentially lead to significant therapeutic effects in multiple inflammatory, autoimmune, and hematologic diseases. The molecule is in phase III development as a combination therapy for patients with haematological malignancies such as chronic lymphocytic leukemia and follicular lymphoma. ^NCATS

Chemistry

SMILES: C[C@H](NC1=NC=NC2=C1N=CN2)C3=CC4=C(C(Cl)=CC=C4)C(=O)N3C5=CC=CC=C5
InChIKey: SJVQHLPISAIATJ-ZDUSSCGKSA-N
Mol. Mass: 416.863
ALogP: 4.48 Partition coefficient
ChEMBL Molecule:
duvelisib

More Chemistry

Pharmacology

Mechanisms of Action:
- Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform (Homo sapiens) ^UniProt
- Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform (Homo sapiens) ^UniProt
Multi-specific: Missing data
Black Box: No
Availability: Missing data
Delivery Methods: Missing data
Pro Drug: No

Drug Pricing (per unit)

United States

$118.0395 - $215.0505

More Pricing Detail

Note: This drug pricing data is preliminary, incomplete, and may contain errors.

8-chloro-2-phenyl-3-((1s)-1-(9h-purin-6-ylamino)ethyl)-1(2h)-isoquinolinone | duvelisib | ink-1147 | ink-1197 | ipi-145

Organizations (23)

Research & Development (23)

Organization	Org Type	FDA approvals	Clinical Trials involvement	Org ID	Force Sort

Marketing (2)

Organization	Org Type	FDA approvals	Clinical Trials involvement	Org ID	Force Sort

Indications (27)

Approved Indications (2)

Leukemia, Lymphocytic, Chronic, B-Cell (approved 2018)

Lymphoma, Follicular (approved 2018)

Experimental Indications - Clinical Trial Phases 1-4 (27)

Arthritis, Rheumatoid (Phase 2)

Asthma (Phase 2)

COVID-19 (Phase 2)

Enteropathy-Associated T-Cell Lymphoma (Phase 2)

Healthy Volunteers (Phase 1)

Hematologic Neoplasms (Phase 2)

Hodgkin Disease (Phase 1)

Intestinal Neoplasms (Phase 2)

Leukemia (Phase 2)

Leukemia, Lymphocytic, Chronic, B-Cell (Phase 3)

Leukemia, Lymphoid (Phase 1)

Leukemia-Lymphoma, Adult T-Cell (Phase 1)

Liver Diseases (Phase 1)

Lymphoma (Phase 2)

Lymphoma, B-Cell, Marginal Zone (Phase 3)

Lymphoma, Extranodal NK-T-Cell (Phase 1)

Lymphoma, Follicular (Phase 3)

Lymphoma, Large B-Cell, Diffuse (Phase 1)

Lymphoma, Non-Hodgkin (Phase 3)

Lymphoma, Primary Cutaneous Anaplastic Large Cell (Phase 2)

Lymphoma, T-Cell (Phase 2)

Lymphoma, T-Cell, Peripheral (Phase 2)

Melanoma (Phase 2)

Multiple Myeloma (Phase 1)

Precursor Cell Lymphoblastic Leukemia-Lymphoma (Phase 1)

Sezary Syndrome (Phase 1)

Squamous Cell Carcinoma of Head and Neck (Phase 2)

Overview

Highest Phase: Phase 3
# of Trials: 47
# of Trial Organizations: 23

Trials by Phase

Trial	Phase	Start Date	Organizations	Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue